Prevention of Venous Thromboembolism Disease in Emergency Departments
NCT ID: NCT01212393
Last Updated: 2018-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20000 participants
OBSERVATIONAL
2009-09-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We aim to analyse the incidence of symptomatic thromboembolic disease following hospitalisation in medical setting and the efficacy of a multicomponent prevention approach in emergency department including systematic evaluation of thrombosis risk factors and remembers of thrombophylaxis indications and modalities for acutely ill medical patients.
Design: cluster randomized interventional study - Observational study at patient level
Setting: 30 French emergency departments
Patients: Patients over 40 years old admitted in participating emergency departments and hospitalized for acute medical reasons.
Main judgment criteria: the rate of symptomatic thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
NCT04439383
Cohort for Monitoring Patients With Venous Thromboembolic Disease
NCT07016542
Venous Thromboembolism Prophylaxis in Medical and Surgical ICUs in a Single University Hospital
NCT01851239
Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure
NCT03206372
A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients
NCT02213978
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At the end of an observational period of a week, centers will be randomized in two groups: intervention or current practice. In the intervention group, centers will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment. We will propose no change in current practice in the other group.
Primary outcome: the rate of symptomatic venous thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.
All possible thromboembolic events, severe haemorrhages and deaths will be analysed by an adjudication committee blinded of group assignation. Sudden death without obvious cause according to the adjudication committee will be considered as possible fatal pulmonary embolism.
Sample size: We calculated sample size on the basis of primary outcome. Assuming the participation of 30 centers (15 in each group), an intracluster correlation of 0.01, a rate of symptomatic thromboembolic events or severe haemorrhage of 5% in the current practice group, we need a sample of 16170 patients (8085 in each group) to detect a 1.5 percentage absolute difference between the 2 groups (3.5% in the intervention group) with a power of 80% and a significance level of 5%.
Considering a rate of patients hospitalized less than 48 hours around 5% and of lost of follow-up around 3%, we anticipated to include 16500 patients for the main analysis and 18000 patients for the overall study.
Secondary outcomes:
* The appropriateness of thromboprophylaxis in the overall population and according to group assignation:
* Number of patients needing prevention treatment according to international recommendations and who have an appropriate treatment.
* Number of patients without indication of thromboprophylaxis and who do not receive a treatment
* The rate of symptomatic venous thromboembolic events during a formal 3-months follow-up after hospital admission
* in all included patients
* in patients hospitalized at least 48 hours.
* inpatients hospitalized less than 48 hours
* The rate of thromboembolic events
* in patients who had an appropriate thromboprophylactic treatment
* in patients who had an inappropriate thromboprophylactic treatment
* in patients who had no thromboprophylactic treatment
* The rate of severe haemorrhage
* in patients who had an appropriate thromboprophylactic treatment
* in patients who had an inappropriate thromboprophylactic treatment
* in patients who had no thromboprophylactic treatment
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
reminders
reminders
In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
current practice group
no intervention
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
reminders
In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Emergency department admission for non-traumatic reason
* Hospitalization in medical setting
Exclusion Criteria
* patients hospitalized in a facility which doesn't participate to the study
* 3 months follow-up not possible
* patients refusing that their personal data are used for medical research
* patients refusing to be reach for the 3 months follow-up
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Angers
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre-Marie ROY, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
UH Angers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UH Agen
Agen, , France
H Argenteuil
Argenteuil, , France
UH Besançon
Besançon, , France
H Bethune
Béthune, , France
H Bobigny
Bobigny, , France
UH Ambroise Pare
Boulogne-Billancourt, , France
UH Brest
Brest, , France
H Chateauroux
Châteauroux, , France
H Clermont Ferrand
Clermont-Ferrand, , France
H Compiegne
Compiègne, , France
UH Dijon
Dijon, , France
UH Grenoble
Grenoble, , France
UH La Reunion
La Réunion, , France
UH Marseille
Marseille, , France
UH Metz Thionville
Metz, , France
UH Nantes
Nantes, , France
UH Nimes
Nîmes, , France
UH la pitié salpetriere
Paris, , France
H Cochin
Paris, , France
UH Bichat
Paris, , France
UH Hotel Dieu
Paris, , France
UH Poitiers
Poitiers, , France
UH Rennes
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Roy PM, Rachas A, Meyer G, Le Gal G, Durieux P, El Kouri D, Honnart D, Schmidt J, Legall C, Hausfater P, Chretien JM, Mottier D; PREVENU study group. Multifaceted Intervention to Prevent Venous Thromboembolism in Patients Hospitalized for Acute Medical Illness: A Multicenter Cluster-Randomized Trial. PLoS One. 2016 May 26;11(5):e0154832. doi: 10.1371/journal.pone.0154832. eCollection 2016.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHRC 2008-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.